. Author manuscript; available in PMC: 2016 Aug 21.

Published in final edited form as: ACS Chem Biol. 2015 May 22;10(8):1887–1896. doi: 10.1021/acschembio.5b00101

Table 1.

Ability of various DAAs to inhibit the genotype 1b subgenomic replicons and Huh7.5 cell viability

Compound	EC₅₀ (μM)^a	CC₅₀ (μM)^b
HPI	15 ± 4	>100
Telaprevir	0.81 ± 0.4	45 ± 4
Boceprevir	0.64 ± 0.1	> 100
Danoprevir	0.002 ± 0.0005	100
Grazoprevir	0.00076 ± 0.00013	54 ± 5

EC₅₀ values represent the concentration of each compound needed to reduce cellular HCVsg 1b(con1)-Rluc replicon content by 50% relative to cells treated with DMSO alone.

CC₅₀ values are concentrations needed to reduce cell viability by 50%.